- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Data Protection
- Design
- Digital Marketing Rights
- DRM
- Electronics
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
U.S. District Court Confirms Validity of Patent For UCB Pharma’s Vimpat®
August 17, 2016 - 5:19 am
Categories:
News & Updates
Patent Litigation
Patents
pharma
Pharma/Biotech Patent Litigations
USPTO
0 Comments UCB Pharma, a Belgian pharmaceutical company, announced on 14th August 2016 that the U.S. District Court for the District of Delaware confirmed the validity of its U.S. reissued patent RE38551 related to anti-epileptic drug Vimpat® (lacosamide). The patent challenge was brought by generic drug makers who had questioned the validity of the UCB’s patent which … Continue reading U.S. District Court Confirms Validity of Patent For UCB Pharma’s Vimpat®
Read more »Federal Circuit Rules 180-Day Post-Licensure Notice is Mandatory in Biosimilar Litigation
July 11, 2016 - 4:37 am
Categories:
IP Litigation
News & Updates
patent infringement
Patent Litigation
Patents
Pharma/Biotech Patent Litigations
0 Comments In Amgen v. Apotex (No. 2016-1308), the US Court of Appeals for the Federal Circuit on July 5, 2016 affirmed a district court’s ruling that a biosimilar applicant must provide a reference product sponsor with 180 days’ post-licensure notice before commercial marketing of a biosimilar product begins, regardless of whether the applicant provided the § … Continue reading Federal Circuit Rules 180-Day Post-Licensure Notice is Mandatory in Biosimilar Litigation
Read more »Revocation of Valganciclovir patent by Controller of Patents, Chennai
August 1, 2015 - 9:46 am
Categories:
IPAB
IPAB Decisions
News & Updates
Patent Opposition
Patents
pharma
Pharma/Biotech Patent Litigations
Section 3(D)
0 Comments Recently in a matter remanded from IPAB to Controller of Patents, Chennai, a decision of revoking Roche’s patent IN207232 for Valganciclovir was delivered after hearing both the parties. The subject patent was granted on January, 2009 followed which post grant oppositions were separately filed by CIPLA, Matrix, Ranbaxy and Bakul Pharma along with two NGOs … Continue reading Revocation of Valganciclovir patent by Controller of Patents, Chennai
Read more »Division Bench of Delhi High Court passed an interim order in Glenmark v. Symed (July 2015)
July 27, 2015 - 7:22 am
Categories:
India
IP Litigation
News & Updates
patent infringement
Patent Litigation
Patents
pharma
Pharma/Biotech Patent Litigations
0 Comments The High Court of Delhi has passed an interim order wherein the Justices have made it clear that the appellant (Glenmark) may use any other process which may be a development of the Glenmark process / Upjohn process so long as it does not infringe the patented processes of the respondent (Symed). Background: Symed Laboratories … Continue reading Division Bench of Delhi High Court passed an interim order in Glenmark v. Symed (July 2015)
Read more »Supreme Court stayed the Delhi High Court order of injunction against Glenmark over the Generic drug “Sitagliptin”
April 2, 2015 - 10:04 am
Categories:
India
IP Litigation
IP Practice in India
News & Updates
patent infringement
Patent Litigation
Patents
pharma
Pharma/Biotech Patent Litigations
0 Comments Reportedly, Hon’ble Supreme Court of India on Special Leave Petition filed by Glenmark stayed the Delhi High Court order which passed an injunction against Glenmark for the generic drug Sitagliptin till 28th April 2015. The Delhi high court dated 20th March 2015 set aside an order of a single-judge bench of Delhi High Court which … Continue reading Supreme Court stayed the Delhi High Court order of injunction against Glenmark over the Generic drug “Sitagliptin”
Read more »Cipla’s plea for revocation of Novartis Patents for Onbrez may face major set back by the Government
December 17, 2014 - 8:25 am
Categories:
India
IP Litigation
IP Practice in India
News & Updates
Patent Litigation
Patents
pharma
Pharma/Biotech Patent Litigations
0 Comments As reported in TOI, the Indian Government has found very little merit in Cipla’s plea for waiver and cancellation of Patent rights for chronic obstructive pulmonary disease (COPD) drug over which Novartis has exclusive rights. We have reported on Cipla’s plea here. Background: Cipla, previously approached the Department of Industrial Policy and Promotion (DIPP) to … Continue reading Cipla’s plea for revocation of Novartis Patents for Onbrez may face major set back by the Government
Read more »Cipla Files Representation with Govt. Seeking Revocation of Novartis’ Patents
November 1, 2014 - 5:27 pm
Categories:
India
IP Litigation
IP Practice in India
News & Updates
Patent Litigation
Patents
pharma
Pharma/Biotech Patent Litigations
0 Comments It has been recently reported in Economic times that Cipla has filed representation with the government (Department of Industrial Policy & Promotion) seeking revocation of five patents of Novartis on indacaterol, a respiratory drug for the treatment of chronic obstructive pulmonary disease (COPD) and marketed as Onbrez by Novartis. The central government, under section 66 … Continue reading Cipla Files Representation with Govt. Seeking Revocation of Novartis’ Patents
Read more »Why Protecting Patents in India is Giving Hard Time to Drug Patent Holders
May 22, 2014 - 10:34 am
Categories:
India
IP Litigation
News & Updates
Patent Litigation
Patents
Pharma/Biotech Patent Litigations
0 Comments Introduction A lot has been discussed on the Novartis ruling indicating much higher standards of patentability under Indian law under section 3d. The ruling decided that any new form of known compound (in medicine) would be patentable only if there is enhanced ‘therapeutic efficacy’ over the known compound. Post Novartis ruling, a couple of patent … Continue reading Why Protecting Patents in India is Giving Hard Time to Drug Patent Holders
Read more »GSK’s patent on lapatinib ditosylate revoked by IPAB
August 8, 2013 - 9:36 am
Categories:
IP Practice in India
Pharma/Biotech Patent Litigations
0 Comments GSK’s granted patent IN221171 (‘171) on lapatinib ditosylate (marketed as Tykerb), a tyrosine kinase inhibitor for treating breast cancer, was revoked by IPAB by its order of 27th July 2013. A revocation application was filed by Fresenius Kabi Oncology Limited. The patent is revoked on the ground of non-compliance with S.3d alone on basis of … Continue reading GSK’s patent on lapatinib ditosylate revoked by IPAB
Read more »Monsanto’s Patent on Method of Producing Transgenic Plants refused by IPAB
Monsanto’s Indian patent application 2407/DEL/NP/2006 on transgenic plants with heat/salt/drought tolerant plants is rejected by IPAB. The subject patent application is directed to a method of producing a draught/stress/heat/salt/drug-tolerant transgenic plants by inserting a recombinant DNA molecule that expresses a cold shock protein CspA or CspB. The subject patent application was rejected by the Controller … Continue reading Monsanto’s Patent on Method of Producing Transgenic Plants refused by IPAB
Read more »